Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.55
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutes

Wed, 21st Feb 2024 16:57

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors anxiously look ahead to this evening's Federal Open Market Committee meeting minutes.

The FTSE 100 index closed down 56.70 points, 0.7%, at 7,662.51. The FTSE 250 ended up 9.34 points at 19,118.97, and the AIM All-Share closed down 3.03 points, or 0.4%, at 750.02.

The Cboe UK 100 ended up 0.7% at 767.16, the Cboe UK 250 closed up marginally at 16,527.66, and the Cboe Small Companies ended down 0.1% at 14,469.48.

Stocks in New York were lower at the London equities close, with the DJIA down 0.1%, the S&P 500 index down 0.2%, and the Nasdaq Composite down 0.5%.

Minutes from the January Federal Open Market Committee meeting will be released at 1900 GMT.

At that meeting, the Federal Reserve Chair Jerome Powell said that a cut in interest rates in March is not the "most likely case". Since his comments, strong consumer and wholesale price inflation figures have backed this wait-and-see stance.

Investors will be hoping for some more clues on the Fed's future monetary policy.

AJ Bell's Russ Mould said: "The Fed kept rates unchanged for the fourth time in a row at the January meeting and indicated it was not ready to start cutting. The meeting minutes should lift the lid on this thinking and more likely spell out that inflation needs to come down further before the central bank reaches for the scissors."

Investors are also nervously eyeing quarterly results from Nvidia, which are due after the closing bell in New York. Its shares were down 2.2% in New York.

"The market is keenly awaiting Nvidia's earnings release after the market's close to assess the mega cap's performance and its potential to sustain the recent rally in the market. Given the continuing enthusiasm for artificial intelligence and the industry's impact on sentiment, the company's results could have a significant influence on the market as a whole," Ali Jaffar at DHF Capital explained.

The pound was quoted at USD1.2622 at the London equities close Wednesday, lower compared to USD1.2649 at the close on Tuesday. The euro stood at USD1.0812 at the European equities close Wednesday, down against USD1.0818 at the same time on Tuesday. Against the yen, the dollar was trading at JPY150.25, higher compared to JPY149.84 late Tuesday.

Markets in Europe were outperforming those in London.

In European equities on Wednesday, the CAC 40 in Paris ended up 0.2%, while the DAX 40 in Frankfurt ended up 0.3%.

In Paris, Carrefour shares jumped 5.3%.

The Massy, France-based retailer said adjusted net income in 2023 rose 7.6% to EUR1.30 billion from EUR1.21 billion the year before. Adjusted earnings per share climbed 12% to EUR1.83 in 2023 from EUR1.63 in 2022.

Carrefour also set an annual dividend growth target of at least 5% on this higher base and launched a new EUR700 million share buyback program in 2024.

Back in London, HSBC plummeted 8.4%.

HSBC announced further share buybacks as annual profit soared on the back of higher interest rates, although its fourth-quarter performance suffered due to an impairment.

The Asia-focused lender said pretax profit in 2023 surged 78% to USD30.35 billion from USD17.06 billion. Total revenue rose 30% to USD66.06 billion, from USD50.62 billion.

HSBC said it has approved a fourth interim dividend of USD0.31 per share, bringing the total dividend to USD0.61 per share, almost double that of USD0.32 in 2022. HSBC also said it will begin a share buyback of up to USD2.0 billion, which it expects to complete by the announcement of its first quarter results.

In the FTSE 250, shares in Bytes Technology tumbled 11% after the sudden exit of its Chief Executive Neil Murphy.

Bytes said Murphy had resigned with immediate effect after disclosing to the board a number of undisclosed trades in the company.

The trades were not disclosed to the company or the market in compliance with the PDMR disclosure requirements, it added.

Bytes said it was working to clarify the details of the undisclosed trades.

The company said Sam Mudd, executive director and managing director of Phoenix Software, will assume the role of interim CEO.

On AIM, Shield Therapeutics shares sunk 51%.

The commercial-stage pharmaceutical company said it was expecting stellar results for 2023, but this success was overshadowed by a mistake in the company's previous prescription forecasts.

Total prescriptions tripled over the year to around 77,000. However, this was markedly down from the company's previous forecasts of between 100,000 and 130,000.

Shield said that this was due to a mistake in the projection methodology used by its third-party data provider, which resulted in a significant overstatement of total prescriptions over the year. The company said it was working with its data provider to ensure that these data mistakes are not repeated, and will provide an additional update alongside its full results.

Brent oil was quoted at USD82.84 a barrel at the London equities close Wednesday, up from USD82.09 late Tuesday. Gold was quoted at USD2,024.88 an ounce at the London equities close Wednesday, lower against USD2,027.87 at the close on Tuesday.

In Thursday's UK corporate calendar, there are full year results from Anglo American, Hikma Pharmaceuticals, Rolls-Royce, Lloyds and WPP.

The economic calendar for Thursday has a slew of PMI data. There is also the weekly US initial jobless claims.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
17 Apr 2019 18:11

DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP40,000 In Shares

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday Chair James Karis bought 50,000 shares in the company.Karis acquired 46,000 shares at GBP0.815 on Monday, then acquired a at

Read more
3 Apr 2019 10:10

Shield Therapeutics narrows losses as it advances Feraccru to market

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced a decent improvement in revenue in its preliminary results on Wednesday, to £11.9m from £0.6m.

Read more
3 Apr 2019 09:56

Shield Therapeutics Cuts Loss In 2018; Licence Payment Lifts Revenue

LONDON (Alliance News) - Drug maker Shield Therapeutics PLC said Wednesday its 2018 loss narrowed significantly as revenue surged on a licence payment boost amid a year of "transition" a

Read more
14 Mar 2019 15:52

Shield Therapeutics Secures Positive Decision On Feraccru's Patent

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said its Feraccru patent met the requirements of the European Patent Convention, which will continue to provide protection to Feraccru

Read more
4 Mar 2019 11:26

Shield Therapeutics upbeat on latest Feraccru trial results

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the AEGIS-H2H clinical trial on Monday, which compared 'Feraccru' (ferric maltol) - a novel oral iron replacement therapy - to 'Ferinject' (ferric carboxymaltose - FCM), the market-leading intravenously delivered iron replacement therapy.

Read more
29 Jan 2019 11:21

Shield Therapeutics Gets Positive Results From Feraccru Study

LONDON (Alliance News) - Shield Therapeutics PLC on Tuesday reported positive results from a long-term study of its lead treatment for iron deficiency, Ferracru.Shares in the company were a

Read more
29 Jan 2019 10:02

Shield Therapeutics upbeat on results of latest Feraccru study

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the open-label extension phase of the AEGIS-CKD pivotal study of 'Feraccru' on Tuesday.

Read more
24 Jan 2019 14:16

Shield Therapeutics Expects 2018 Revenue Growth On Licence Payments

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said it expects its revenue to surge in 2018 on the back of licence payments for its Feraccru capsules.The pharmaceutical has in

Read more
24 Jan 2019 10:02

Shield Therapeutics revenues surge following commercialisation deal

(Sharecast News) - Shield Therapeutics saw revenues rocket in the second half of its trading year following a commercialisation agreement with European pharmaceutical specialist Norgine.

Read more
22 Jan 2019 13:35

Shield Therapeutics Appoints Director James Karis As Chair

LONDON (Alliance News) - Shield Therapeutics PLC said Tuesday that it has promoted board member James Karis to be non-executive chair with immediate effect.Karis has served on Shield's

Read more
22 Jan 2019 09:56

Shield Therapeutics promotes Karis to chairman

(Sharecast News) - Commercial stage pharmaceutical outfit Shield Therapeutics elevated James Karis to the role of non-executive chairman on Tuesday.

Read more
13 Dec 2018 11:57

FDA gives target date for Shield's Feraccru application

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced on Thursday that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of 'Feraccru', under the terms of the Prescription Drug User Fee Act, would be 27 July 2019.

Read more
5 Dec 2018 13:07

Shield Therapeutics' Feraccru treatment launched in UK

(Sharecast News) - Shield Therapeutics' treatment for iron deficiency in adults, Feraccru, was launched in the UK on Wednesday by specialist pharmaceutical company Norgine.

Read more
5 Dec 2018 11:57

Shield Therapeutics Partner Norgine Launches Feraccru In UK

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday that Norgine BV has launched the company's treatment for iron deficiency, Ferracru, in the UK.In September 2018, Shield,

Read more
24 Sep 2018 14:30

DIRECTOR DEALINGS: Shield Therapeutics Boss Sterritt Buys More Stock

LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Chief Executive Carl Sterritt bought more shares in the company in a deal on Friday last week.Sterritt pruchased 88,235 at 34

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.